Zepbound
14 articles on Zepbound, written by Shotlee and medically reviewed for clinical accuracy.
Is Ozempic Behind Charles Barkley's Weight Loss? Slim Look Stuns in March Mad...
Charles Barkley's noticeably slimmer figure courtside during March Madness 2026 has sparked widespread speculation: Is Ozempic behind his weight loss? The NBA legend dropped nearly 90 pounds using GLP-1 drugs like Mounjaro and Zepbound, combined with diet and exercise. Fans are stunned, but Barkley credits hard work over hype.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
Could Ozempic and GLP-1s Help ADHD Symptoms?
People with ADHD report feeling calmer and more focused on GLP-1 drugs like Ozempic, originally for obesity and diabetes. Experts explain potential links to dopamine and reduced food cravings, but stress no clinical trials prove direct benefits. Find out the real story behind social media buzz and what to discuss with your doctor.
5 min read
Amazon Pharmacy Adds Zepbound KwikPen to Same-Day Delivery
Amazon Pharmacy is streamlining GLP-1 access by adding Zepbound KwikPen to its same-day delivery service. This multi-dose device holds a full month's supply, addressing manufacturing bottlenecks and offering $299 cash-pay pricing—far below traditional $1,000 quotes. Integrated with Amazon One Medical, it provides personalized care for weight management and obstructive sleep apnea patients.
4 min read
How Eli Lilly Used AI to Boost Zepbound & Mounjaro Production
While AI hype focuses on drug discovery, Eli Lilly has quietly used it to supercharge manufacturing of its blockbuster GLP-1s, Zepbound and Mounjaro. This led to record production volumes that avoided FDA shortages and fueled massive revenue growth. Here's how they did it with digital twins and defect detection tech.
7 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
Weight-Loss Drugs Compete in Super Bowl Ads: Wegovy Leads
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
5 min read
Woman's 39-lb Breasts Won't Stop Growing: Gigantomastia Discovered on Mounjaro
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
5 min read
Eli Lilly Shares Face Pressure Amid GLP-1 Market Shifts
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
5 min read
Child Ozempic Overdose: Risks, Symptoms & Prevention Guide
When 7-year-old Jessa injected her mom's Ozempic thinking it was stomach medicine, she faced severe vomiting, dehydration, and kidney risks. This incident underscores the dangers of GLP-1 medications like semaglutide and tirzepatide in children. Discover prevention tips and what to do in an emergency.
4 min read
GLP-1 Drugs Force Restaurant Chains to Shrink Menus
GLP-1 weight loss drugs like Ozempic and Wegovy are transforming restaurant menus. Major chains now provide smaller servings and protein-rich items as users eat less but prioritize quality. A recent poll shows 12% of Americans on these medications.
1 min read
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.
2 min read
Zepbound at Walmart: Expanding Access to GLP-1 Medications for Weight Loss
Eli Lilly's Zepbound is now available at Walmart pharmacies, making it easier for individuals to access this GLP-1 medication. This expansion offers a convenient option for those seeking weight loss support and managing their metabolic health.
3 min read